Alnylam’s Blood Pressure Drug: Not Exactly Heartwarming Yet
Alnylam just dropped data from their so-called 'investigational therapy' that was supposed to be the Tesla of blood pressure meds but ended up more like a tricycle. Their Phase 2 trial, aka the 'Thrill of Mediocrity,' didn't significantly lower blood pressure. Yet, in a plot twist worthy of a soap opera reboot, the company decided to plunge forward into a late-stage study—because why quit when you can pretend progress? No dollar amounts or dates were shared, but one thing’s clear: Alnylam is writing a new chapter in the 'Lower Your Expectations' saga. If clinical trials were auditions, this one got a polite nod to keep trying.
Share the Story
Alnylam’s blood pressure med didn’t budge the dial, but hey, let’s double down on hope and move to late stage—because who doesn’t love trying the same thing harder until it magically works?
Who knew the secret to clinical success is a solid game of pretend? Alnylam’s drug flopped Phase 2 yet gets a free pass to late stage like it’s the kid who flunked math but still makes varsity cheerleading.
'Significantly lowers blood pressure' took a sick day, but Alnylam’s optimism shows up on time and boots—time to double down on science’s version of 'hold my beer.'
Source: Statnews | Published: 8/30/2025 | Author: Elaine Chen
More Articles in Health
Trump Promises Retirement Plan That Matches Generosity of Federal Workers’ Excuses
Trump Calls Supreme Court 'Unfortunate,' Then Hits Economy with ‘Better’ 10% Global Tariff
Sydney Sweeney's $1M Flop, Trump-Approved Jeans & Bathwater Soap Fiasco
Mom Skips Junior Year Exams, Swaps Algebra for Penguins in Antarctica
America Solves Fentanyl Crisis by Inventing Pink Cocaine Zombie Apocalypse
French Obesity Rate Mystifies US After Cheese, Wine, Bread Diet Approved
Woman Waited Years to Wear Favorite Clothes; Life Finally Happened, Clothes Revolted
RFK Jr. Promises To Investigate Ultra-Processed Junk Food but Won't Regulate It
